

Press release about Scorpion's clinical trials (March 1, 2009)

Scorpion Announced Successful Pre-Clinical Trial with the Company's Unique Spinal Implant


The curved anchoring device trial was performed following a successful experiment in a bio-mechanical lab in Innsbruck, Austria

Scorpion Surgical Technologies reports a successful pre-clinical cadaver test. During the test, the company's unique curved spinal anchoring device was connected to two vertebrae.

Dr. Nissim Ohana, Head of Spine Department in Rabin Hospital, Petah Tikva, was in charge of the test. This test followed a successful bio-mechanical test performed in the laboratory of Dr. Werner Schmolz in Innsbruck, Austria.

Scorpion has developed an innovative implant for fusion procedures in cases of disc eruption or chronic pains resulting from movement of vertebrae. The curved anchoring device enables a better hold of the vertebra and longer durability of the device throughout the years, compared to other devices.

The device has particular value for osteoporotic patients. By enabling a tight grip despite the soft bone, it is expected to prevent loosening on the vertebra and the need for periodic revision surgery.



Yaron Aizenbud, Scorpion CEO, noted that "we are thrilled to receive the excellent results of the test. The cadaver test results reinforce the work and planning invested in developing the product. We are now preparing for the Regulatory procedure to receive approval for human clinical trials".



Scorpion's is advised by a number of world renowned surgeons who are supporting the development process and will participate in clinical trials of the unique device and related surgical equipment.

Scorpion was established in 2006 and is starting its third year in the Misgav Venture Accelerator. It was founded by four entrepreneurs: Dr. Nissim Ohana – Head of the Spine Department in Rabin Hospital, Dr. Assaf Ben-Arie, Dr. Yuval Shezifi – biomechanics expert and Ilan Greenberg – mechanics expert. The spinal surgery market is estimated at 5 billion dollars yearly worldwide.

About Misgav Venture Accelerator

The Misgav Venture Accelerator (<http://www.misgav-venture.com>) was founded in 1992. It is an early-stage investor focusing on the life sciences - medical devices, pharmaceuticals, and biotechnology. The Misgav Venture Accelerator is a subsidiary of The Trendlines Group, which establishes and supports early stage companies in Israel through its two incubators – Misgav and Mofet Innovation Accelerator – and through its business development firm, Trendlines International.